Safety and Efficacy of HB-1 for Panic Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Panic Disorder

In brief

The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.

Key facts

Study ID

NCT05071430

Run by

HB BioTech, LLC

People needed

86

Starts

2022-02-03

Expected to finish

2022-12-12

Last updated by the study team

2025-03-18

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Collaborative Neuroscience Research — Garden Grove, California, United States
• Lumos Psychiatric Services — San Jose, California, United States
• Institute of Living — Hartford, Connecticut, United States
• CNS Healthcare — Jacksonville, Florida, United States
• CNS Healthcare — Orlando, Florida, United States
• Uptown Research Institute — Chicago, Illinois, United States
• Hassman Research Institute — Berlin, New Jersey, United States
• SPRI Clinical Trials — Brooklyn, New York, United States
• Richmond Behavioral Associates — Staten Island, New York, United States
• CNS Healthcare — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.